Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Saturday, February 6 2016 10:53am ET - U.S. Markets Closed.
Industry Center
Industry Center > > UCB SA Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
UCB SA Company Profile
You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS). The company manufacturers prescription drugs to treat Crohn's disease, epilepsy, and Parkinson's disease. UCB's top products include Cimzia for Crohn's disease,Vimpat to treat epilepsy, and Neupro for Parkinson's disease. The company also makes allergy blockbuster Zyrtec. UCB has operations in nearly 30 countries, and markets its products through an internal sales force and through strategic relationships with other pharmaceutical companies. Marketing, manufacturing, and development partners include AstraZeneca and Novartis. Financière de Tubize owns a majority stake in UCB.
Headlines for UCB SA
UCB reinforces its commitment to epilepsy research with a strong presence at the 2015 American Epilepsy Society annual meeting
PR Newswire - Fri Dec 4
Lannett Completes Major Acquisition Of Kremers Urban Pharmaceuticals For $1.23 Billion
PR Newswire - Fri Nov 27
UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting
PR Newswire - Fri Nov 6
UCB SA – Value Analysis (US OTC:UCBJY) : October 22, 2015
- Thu Oct 22
More Headlines...
More on UCB SA
Quote    
Profile    
Contact Information
Address: Allée De La Recherche 60
Bruxelles, Bruxelles-Capitale 1070, Belgium
Phone:+32-25599999
Fax:+32-25599900
Financial Highlights
Fiscal Year End:December
Revenue (2014):4064.60 M
Revenue Growth (1 yr):(-13.40%)
Employees (2014):8,684
Employee Growth (1 yr):(-0.50%)
Key People
Chairman: Gerhard N. Mayr
Chairman and CEO: Jean-Christophe Tellier
Vice Chair: Evelyn du Monceau
Industry Information
Sector:
Industry:
Top Competitors
Cephalon, Inc.
PFIZER INC. (pfe)
JOHNSON & JOHNSON (jnj)
 


Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2016 Morningstar, Inc. All Rights Reserved. Company information © 2016 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2016, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?